Can-Fite BioPharma (CANF) Current Taxes (2016 - 2017)
Can-Fite BioPharma (CANF) posted Current Taxes of $1.5 million for Q4 2017, down 69.21% quarter-over-quarter from $4.8 million in Q4 2016, and down 69.21% YoY from $4.8 million in Q4 2016.
Powered by 
Analysis
Can-Fite BioPharma (CANF) Current Taxes (2016 - 2017) Analysis & Trends
Can-Fite BioPharma (CANF) has 2 years of Current Taxes data on file, last reported at $1.5 million in Q4 2017.
- For the quarter ending Q4 2017, Current Taxes fell 69.21% year-over-year to $1.5 million; the trailing twelve-month figure through Dec 2017 stood at $1.5 million (down 69.21% YoY), and the FY2017 full-year result was $1.5 million, down 69.21% from the prior year.
- Current Taxes was $1.5 million for Q4 2017 at Can-Fite BioPharma, down from $4.8 million in the prior quarter.
- In the past five years, Current Taxes ranged from a high of $4.8 million in Q4 2016 to a low of $1.5 million in Q4 2017.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Taxes (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 649.12 Bn | 628.36 Bn | 17.26 Bn | 1.05 Bn |
| 2 | AbbVie | 445.86 Bn | 439.29 Bn | 12.70 Bn | - |
| 3 | Merck | 362.13 Bn | 354.99 Bn | 12.21 Bn | 4.22 Bn |
| 4 | Novartis Ag | 268.88 Bn | 261.19 Bn | 11.24 Bn | 2.31 Bn |
| 5 | Pfizer | 156.96 Bn | 145.26 Bn | 10.94 Bn | 653.00 Mn |
| 6 | Sanofi | 52.26 Bn | 44.88 Bn | 10.79 Bn | 1.03 Bn |
| 7 | Revolution Medicines | 42.98 Bn | 42.98 Bn | - | - |
| 8 | Incyte | 25.13 Bn | 20.59 Bn | 1.57 Bn | - |
| 9 | United Therapeutics | 21.56 Bn | 18.90 Bn | 683.80 Mn | - |
| 10 | Can-Fite BioPharma | 1.80 Mn | -1.19 Mn | - | - |